| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Bei-Sha Tang | |
| Shan-Shan Huang | |||
| Su Yang | |||
| Hui-Ming Yang | |||
| Ji-Feng Guo | |||
| P2860 | cites work | A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington's disease | Q45291617 |
| Revelation of the IFNα, IL-10, IL-8 and IL-1β as promising biomarkers reflecting immuno-pathological mechanisms in porcine Huntington's disease model | Q45294275 | ||
| Distinct neuroinflammatory profile in post-mortem human Huntington's disease. | Q45294444 | ||
| Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. | Q45296827 | ||
| Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse | Q45297101 | ||
| Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin | Q45297223 | ||
| Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. | Q45297497 | ||
| A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. | Q45298582 | ||
| Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease | Q45298602 | ||
| Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease | Q45299150 | ||
| Microglial activation correlates with severity in Huntington disease: a clinical and PET study. | Q45301519 | ||
| Plasma inflammatory biomarkers for Huntington's disease patients and mouse model | Q45301991 | ||
| Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease | Q45304579 | ||
| Microglial activation in presymptomatic Huntington's disease gene carriers | Q45304723 | ||
| Endocannabinoids drive the acquisition of an alternative phenotype in microglia | Q48123098 | ||
| TNF and increased intracellular iron alter macrophage polarization to a detrimental M1 phenotype in the injured spinal cord. | Q50451036 | ||
| Reactive glia show increased immunoproteasome activity in Alzheimer's disease. | Q51055475 | ||
| Huntington disease | Q56083219 | ||
| Comparison of polarization properties of human adult microglia and blood-derived macrophages | Q57041309 | ||
| TLR signaling tailors innate immune responses in human microglia and astrocytes | Q57041985 | ||
| CNS-derived interleukin-4 is essential for the regulation of autoimmune inflammation and induces a state of alternative activation in microglial cells | Q81391451 | ||
| TLR signaling pathways | Q24570127 | ||
| Exploring the full spectrum of macrophage activation | Q24653754 | ||
| Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains | Q26796857 | ||
| The choreography of neuroinflammation in Huntington's disease | Q26828403 | ||
| Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy | Q26849677 | ||
| Mutant huntingtin downregulates myelin regulatory factor-mediated myelin gene expression and affects mature oligodendrocytes | Q27305777 | ||
| A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. | Q27860836 | ||
| NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses | Q27861101 | ||
| A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease | Q27933811 | ||
| Protective Microglia and Their Regulation in Parkinson's Disease | Q28079731 | ||
| Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains | Q28189423 | ||
| Imaging microglial activation in Huntington's disease | Q28292609 | ||
| Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease | Q28317131 | ||
| Human microglia convert l-tryptophan into the neurotoxin quinolinic acid | Q28379366 | ||
| Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice | Q28507134 | ||
| Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity | Q28513938 | ||
| Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats | Q28587110 | ||
| Longitudinal evaluation of the Hdh(CAG)150 knock-in murine model of Huntington's disease | Q28587809 | ||
| The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway | Q29306901 | ||
| Microglia: active sensor and versatile effector cells in the normal and pathologic brain | Q29547240 | ||
| Missing pieces in the NF-kappaB puzzle | Q29547864 | ||
| Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice | Q29615357 | ||
| Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain | Q29617982 | ||
| Human glia can both induce and rescue aspects of disease phenotype in Huntington disease. | Q30381085 | ||
| Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms | Q30492587 | ||
| Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease | Q30581321 | ||
| Neurotoxic reactive astrocytes are induced by activated microglia | Q33602850 | ||
| Changes of peripheral TGF-β1 depend on monocytes-derived macrophages in Huntington disease | Q33644718 | ||
| A restricted population of CB1 cannabinoid receptors with neuroprotective activity | Q33730578 | ||
| Huntington's disease: from molecular pathogenesis to clinical treatment | Q33773061 | ||
| Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice | Q33796172 | ||
| Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors | Q33959395 | ||
| Bone marrow mesenchymal stromal cells drive protective M2 microglia polarization after brain trauma | Q34000812 | ||
| Microglial priming in neurodegenerative disease | Q38196699 | ||
| Microglial dynamics and role in the healthy and diseased brain: a paradigm of functional plasticity | Q38203788 | ||
| The kynurenine pathway and neurodegenerative disease. | Q38378952 | ||
| Alternatively activated microglia and macrophages in the central nervous system. | Q38525488 | ||
| Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease. | Q38620321 | ||
| Functional polarization of neuroglia: Implications in neuroinflammation and neurological disorders. | Q38630105 | ||
| L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences | Q38696755 | ||
| The role of autophagy in modulation of neuroinflammation in microglia | Q38717214 | ||
| TRAM1 Promotes Microglia M1 Polarization | Q38819822 | ||
| Type-2 cannabinoid receptors in neurodegeneration. | Q38906280 | ||
| IL-10 plays a pivotal role in anti-inflammatory effects of resveratrol in activated microglia cells | Q38921416 | ||
| Exploring New Inflammatory Biomarkers and Pathways during LPS-Induced M1 Polarization | Q39016000 | ||
| Early increase of cannabinoid receptor density after experimental traumatic brain injury in the newborn piglet | Q39164958 | ||
| A novel human embryonic stem cell-derived Huntington's disease neuronal model exhibits mutant huntingtin (mHTT) aggregates and soluble mHTT-dependent neurodegeneration | Q39209451 | ||
| Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. | Q40515168 | ||
| Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers | Q40617788 | ||
| An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes | Q40848200 | ||
| Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system | Q41129837 | ||
| Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors | Q42057708 | ||
| Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus | Q42065483 | ||
| Huntington's disease gene (IT15) is widely expressed in human and rat tissues | Q42502776 | ||
| Increased irritability, anxiety, and immune reactivity in transgenic Huntington's disease monkeys | Q42705378 | ||
| Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. | Q43266820 | ||
| Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study | Q43469689 | ||
| Early and progressive accumulation of reactive microglia in the Huntington disease brain | Q43555981 | ||
| Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease | Q43925468 | ||
| Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease | Q45168385 | ||
| Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease | Q34168124 | ||
| Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons | Q34351574 | ||
| Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. | Q34440282 | ||
| Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175. | Q34531481 | ||
| Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates | Q34634976 | ||
| A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model | Q34746889 | ||
| A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease | Q34795840 | ||
| Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities | Q34863910 | ||
| Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration | Q35054916 | ||
| Activated microglia proliferate at neurites of mutant huntingtin-expressing neurons | Q35103285 | ||
| Microglial and macrophage polarization—new prospects for brain repair | Q35394922 | ||
| Call Off the Dog(ma): M1/M2 Polarization Is Concurrent following Traumatic Brain Injury | Q35903835 | ||
| Huntingtons Disease Mice Infected with Toxoplasma gondii Demonstrate Early Kynurenine Pathway Activation, Altered CD8+ T-Cell Responses, and Premature Mortality | Q36128464 | ||
| Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington's Disease | Q36140894 | ||
| Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity | Q36320596 | ||
| Ligand engagement of Toll-like receptors regulates their expression in cortical microglia and astrocytes | Q36416913 | ||
| Cyclic AMP is a key regulator of M1 to M2a phenotypic conversion of microglia in the presence of Th2 cytokines | Q36457510 | ||
| Microglial M1/M2 polarization and metabolic states | Q36547001 | ||
| Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro | Q36959383 | ||
| Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice | Q37072467 | ||
| PIAS1 Regulates Mutant Huntingtin Accumulation and Huntington's Disease-Associated Phenotypes In Vivo | Q37088539 | ||
| VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease. | Q37105051 | ||
| Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease | Q37120339 | ||
| Compartment-Dependent Degradation of Mutant Huntingtin Accounts for Its Preferential Accumulation in Neuronal Processes | Q37162698 | ||
| Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. | Q37253331 | ||
| Frequency of nuclear mutant huntingtin inclusion formation in neurons and glia is cell-type-specific. | Q37456579 | ||
| Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis | Q37602166 | ||
| M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination | Q37687158 | ||
| HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation | Q37697482 | ||
| Reversal of Phenotypic Abnormalities by CRISPR/Cas9-Mediated Gene Correction in Huntington Disease Patient-Derived Induced Pluripotent Stem Cells. | Q37707514 | ||
| Toll-like receptors 2, -3 and -4 prime microglia but not astrocytes across central nervous system regions for ATP-dependent interleukin-1β release. | Q37738372 | ||
| Neuroinflammation in Huntington's disease | Q37763886 | ||
| Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease | Q37846934 | ||
| Mitochondrial disturbances, tryptophan metabolites and neurodegeneration: medicinal chemistry aspects. | Q37994780 | ||
| P921 | main subject | Huntington's disease | Q190564 |
| pathogenesis | Q372016 | ||
| microglia | Q1622829 | ||
| P304 | page(s) | 193 | |
| P577 | publication date | 2017-06-19 | |
| P1433 | published in | Frontiers in Aging Neuroscience | Q21968084 |
| P1476 | title | Microglial Activation in the Pathogenesis of Huntington's Disease | |
| P478 | volume | 9 |
| Q90481753 | Allele-specific genome targeting in the development of precision medicine |
| Q61813371 | Conditioned medium from amniotic cells protects striatal degeneration and ameliorates motor deficits in the R6/2 mouse model of Huntington's disease |
| Q58095253 | Enforced microglial depletion and repopulation as a promising strategy for the treatment of neurological disorders |
| Q90049912 | Heat-Shock Proteins in Neuroinflammation |
| Q92021279 | IKKβ slows Huntington's disease progression in R6/1 mice |
| Q89714624 | Innate sensing of mechanical properties of brain tissue by microglia |
| Q92816537 | Intranasal Administration of Mesenchymal Stem Cells Ameliorates the Abnormal Dopamine Transmission System and Inflammatory Reaction in the R6/2 Mouse Model of Huntington Disease |
| Q89581865 | Lack of RAN-mediated toxicity in Huntington's disease knock-in mice |
| Q48144016 | Maternal immune activation in neurodevelopmental disorders |
| Q89494159 | MiR-124 and the Underlying Therapeutic Promise of Neurodegenerative Disorders |
| Q58737028 | Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches |
| Q63976655 | RNA Sequencing Reveals Small and Variable Contributions of Infectious Agents to Transcriptomes of Postmortem Nervous Tissues From Amyotrophic Lateral Sclerosis, Alzheimer's Disease and Parkinson's Disease Subjects, and Increased Expression of Genes F |
| Q97066909 | Reduced Fractalkine Levels Lead to Striatal Synaptic Plasticity Deficits in Huntington's Disease |
| Q91793275 | Review on Cross Talk between Neurotransmitters and Neuroinflammation in Striatum and Cerebellum in the Mediation of Motor Behaviour |
| Q88960978 | TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31 |
| Q91899926 | Targeting N-Terminal Huntingtin with a Dual-sgRNA Strategy by CRISPR/Cas9 |
| Q60445723 | Targeting the NLRP3 Inflammasome-Related Pathways via Tianeptine Treatment-Suppressed Microglia Polarization to the M1 Phenotype in Lipopolysaccharide-Stimulated Cultures |
| Q48308877 | The Role of Microglia in Diabetic Retinopathy: Inflammation, Microvasculature Defects and Neurodegeneration. |
| Q97518828 | The World Goes Bats: Living Longer and Tolerating Viruses |
| Q97590555 | The longevity-associated variant of BPIFB4 improves a CXCR4-mediated striatum-microglia crosstalk preventing disease progression in a mouse model of Huntington's disease |
| Q46299429 | miR-124-3p attenuates MPP+-induced neuronal injury by targeting STAT3 in SH-SY5Y cells |
Search more.